Axel Schonthal, PhD

Associate Professor of Molecular Microbiology & Immunology

Associate Dean for Biomedical Master's Programs

Image of Axel Schonthal, PhD
Is this your profile? Click to edit

Overview

The Schönthal lab performs preclinical cancer research and pursues anticancer drug development. The main focus is on brain malignancies, which include primary brain cancers (such as glioblastoma) and secondary brain cancers (such as melanoma or breast cancer that has spread to the brain). The work is done in collaboration with Dr. Thomas Chen, a neurosurgeon and Director of the USC Brain Tumor Group. This joint approach supports interdisciplinary efforts that translate laboratory findings to patient applications.

Publications

  • NEO212, a Perillyl Alcohol-Temozolomide Conjugate, Triggers Macrophage Differentiation of Acute Myeloid Leukemia Cells and Blocks Their Tumorigenicity Cancers (Basel). 2022 Dec 09; 14(24). . View in PubMed
  • Detection of perillyl alcohol and its metabolite perillic acid in postsurgical glioblastoma tissue after intranasal administration of NEO100: illustrative case J Neurosurg Case Lessons. 2022 Aug 22; 4(8). . View in PubMed
  • The Monoterpenoid Perillyl Alcohol: Anticancer Agent and Medium to Overcome Biological Barriers Pharmaceutics. 2021 Dec 16; 13(12). . View in PubMed
  • Potentially Curative Therapeutic Activity of NEO212, a Perillyl Alcohol-Temozolomide Conjugate, in Preclinical Cytarabine-Resistant Models of Acute Myeloid Leukemia Cancers (Basel). 2021 Jul 06; 13(14). . View in PubMed
  • Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer Neuro Oncol. 2021 10 01; 23(10):1656-1667. . View in PubMed
  • Phase I trial of intranasal NEO100, highly purified perillyl alcohol, in adult patients with recurrent glioblastoma Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab005. . View in PubMed
  • Neuro Oncol. 2021 01 30; 23(1):63-75. . View in PubMed
  • Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas PLoS One. 2020; 15(9):e0238238. . View in PubMed
  • Pharmacokinetic properties of the temozolomide perillyl alcohol conjugate (NEO212) in mice Neurooncol Adv. 2020 Jan-Dec; 2(1):vdaa160. . View in PubMed
  • Adjuvant effect of low-carbohydrate diet on outcomes of patients with recurrent glioblastoma under intranasal perillyl alcohol therapy Surg Neurol Int. 2020; 11:389. . View in PubMed
  • Efficient brain targeting and therapeutic intracranial activity of bortezomib through intranasal co-delivery with NEO100 in rodent glioblastoma models J Neurosurg. 2019 Mar 15; 132(3):959-967. . View in PubMed
  • Cytotoxic impact of a perillyl alcohol-temozolomide conjugate, NEO212, on cutaneous T-cell lymphoma in vitro Ther Adv Med Oncol. 2019; 11:1758835919891567. . View in PubMed
  • Rare Stochastic Expression of O6-Methylguanine- DNA Methyltransferase (MGMT) in MGMT-Negative Melanoma Cells Determines Immediate Emergence of Drug-Resistant Populations upon Treatment with Temozolomide In Vitro and In Vivo Cancers (Basel). 2018 Sep 28; 10(10). . View in PubMed
  • A perillyl alcohol-conjugated analog of 3-bromopyruvate without cellular uptake dependency on monocarboxylate transporter 1 and with activity in 3-BP-resistant tumor cells Cancer Lett. 2017 08 01; 400:161-174. . View in PubMed